量化COVID-19大流行对37个国家临床试验筛选率随时间的影响
该研究调查并量化COVID-19大流行对美国及全球行业申办临床试验筛选率的负面影响。研究发现COVID-19大流行的严重程度与临床试验筛选率呈负相关,且该关系在大流行的前三个月最强,并跨治疗领域、美国各州及各国一致存在。
要点
- COVID-19大流行严重程度与临床试验筛选率呈负相关。
- 该负相关关系在大流行前三个月最强。
- 负相关关系跨治疗领域、美国各州及各国一致存在。
核心结论
- COVID-19大流行的严重程度与临床试验筛选率呈负相关,且该关系在大流行前三个月最强。
研究设计与样本
- 研究调查并量化COVID-19大流行对美国及全球行业申办临床试验筛选率的负面影响,覆盖37个国家。
主要发现
- COVID-19大流行严重程度与临床试验筛选率呈负相关,该关系在大流行前三个月相比整个大流行期间最强。
- 该负相关统计关系跨治疗领域、美国各州(尽管州级应对存在异质性)及各国均成立。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic has had an unprecedented and disruptive impact on people's health and lives worldwide. In addition to burdening people's health in the short-term in the form of infection, illness, and mortality, there has been an enormous negative impact on clinical research. Clinical trials experienced challenges in ensuring patient safety and enrolling new patients throughout the pandemic. Here, we investigate and quantify the negative impact that the COVID-19 pandemic has industry-sponsored clinical trials, both in the USA and worldwide. We find a negative correlation between the severity of the COVID-19 pandemic and clinical trial screening rate, with the relationship being strongest during the first three months of the pandemic compared to the entire duration of the pandemic. This negative statistical relationship holds across therapeutic areas, across states in the USA despite the heterogeneity of responses at the state-level, and across countries. This work has significant implications for the management of clinical trials worldwide in response to the fluctuating severity of COVID-19 moving forward and for future pandemics.
引用
- McDonald K, Seltzer E, Lu M, et al. Quantifying the impact of the COVID-19 pandemic on clinical trial screening rates over time in 37 countries. Trials. 2023. PMID: 37013558. doi:10.1186/s13063-023-07277-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。